Advertisement


Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico

2023 ASCO Annual Meeting

Advertisement

Paula Aristizabal, MD, MAS, of the University of California, San Diego, and Rady Children’s Hospital, talks about using a health systems strengthening approach to improve leukemia care and survival in a public Mexican hospital in the region of the border between the United States and Mexico. The demonstrated increase in overall survival across a decade after implementation of the program seems to validate the use of such models, not only to improve clinical outcomes, but also to build sustainable hospital capacity, financially and organizationally (Abstract 1502).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Paula Aristizabal, MD: Acute lymphoblastic leukemia is the most common childhood cancer and survival has improved dramatically in high income countries to rates over 80%. Unfortunately, in low and middle income countries, survival has not increased at the same pace. For example, in Mexico, a low income country that is just across the border from the US, survival range is between 10% and 60%. Since in San Diego we share a border with Tijuana, we saw the disparities and we thought that it was our social responsibility to do something about it so we implemented a twinning program and twinning involves when a center of excellence in a high income country partners and collaborates with a center in a low, middle income country. We started this twinning program in 2008 in collaboration with St. Jude Children's Research Hospital, and we were able to implement a new team in Tijuana that was able to provide the best care possible for all the pediatric cancers. Then in 2013, we realized that the burden of leukemia was getting higher and higher and we decided to implement a new model of health system strengthening called the WHO Framework for Action. The WHO Framework for Action has six building blocks that provide all the elements to improve care in a health system. We incorporated the WHO Framework for Action into the already existing twinning model to improve leukemia survival. We provided training to the team in Tijuana. We provided protocols that they could adapt. We provided mentorship and we provided support for a new infrastructure to develop the best possible leukemia care for children with with leukemia in Baja, California, Mexico. After the implementation of the program, survival for leukemia improved from 59% to 65% and, importantly, the survival for standard risk leukemia improved from 73% before implementing the program to 100%, which is totally amazing because that is the same survival that we have in San Diego, just 20 miles from Tijuana. Survival for high risk leukemia improved from 48% to 55%. It wasn't so significant but we know that that is an area of improvement that we hope that we can tackle in our next steps of the program. Our model in Tijuana, combining a twinning program with the WHO Framework for Action, was effective in improving survival in a low and middle income country. This model can be applicable to a partnership between a high income country and a low, middle income country, especially in regions that share a border but also in other low and middle income countries remotely. Something that we learned from COVID is that you can apply many of these models working remotely and we are extremely pleased with these results. Our next steps include the improvement of the survival for patients with high risk leukemia.

Related Videos

Colorectal Cancer

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by environmental exposures (arginine biosynthesis and dietary red meat) were also noted, suggesting possible links with younger age of onset in this disease (Abstract 3510).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer and HRR gene alterations. This regimen also delayed the time to deterioration in global health status and quality of life (Abstract 5004).

Lung Cancer

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat glioblastoma and mesothelioma, the treatment has extended overall survival in this phase III study of patients with metastatic non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, without exacerbating systemic toxicities (Abstract LBA9005).

Bladder Cancer

Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma. Cisplatin-treated patients appeared to derive a greater benefit with atezolizumab than did carboplatin-treated patients (Abstract 4503).

Lung Cancer

Penelope Bradbury, MBChB, on Pleural Mesothelioma: New Results From the IND227 Trial of Cisplatin and Pemetrexed With or Without Pembrolizumab

Penelope Bradbury, MBChB, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with treatment-naive unresectable pleural mesothelioma, cisplatin and pemetrexed with pembrolizumab improved median overall survival with acceptable tolerability (Abstract LBA8505).

Advertisement

Advertisement




Advertisement